Current treatment options in RAS mutant metastatic colorectal cancer patients: a meta-analysis of 14 randomized phase III trials.

Arndt StahlerVolker HeinemannIngrid RicardJobst C von EinemClemens Giessen-JungChristoph Benedikt WestphalenMarlies MichlKathrin HeinrichLisa Miller-PhillipsIvan JelasSebastian StintzingDominik Paul Modest

Published in: Journal of cancer research and clinical oncology (2020)

The therapeutic benefit of additional substances is less distinct in patients with RAS mutated as compared to RAS wildtype metastatic colorectal cancer, especially with regard to OS.

Keyphrases

metastatic colorectal cancer
phase iii
wild type
open label
double blind
end stage renal disease
clinical trial
placebo controlled
phase ii
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
patient reported outcomes